# THE VALUE OF COMBINING LOW DOSE TROSPIUM CHLORIDE WITH TRANSCUTANEOUS POSTERIOR TIBIAL NERVE STIMULATION IN THE TREATMENT OF OVERACTIVE BLADDER IN FEMALES

Abulseoud A<sup>1</sup>, Moussa A<sup>1</sup>, Ibrahim I<sup>2</sup>, Saba E<sup>2</sup>, Hassouna M<sup>1</sup>, Ali G<sup>1</sup>

<sup>1</sup>Department of Genitourinary Surgery, Faculty of Medicine, Alexandria University Egypt, <sup>2</sup>Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Alexandria University Egypt.

### Introduction

- About 70% of OAB patients discontinue treatment in the first year after starting anticholinergic drugs mainly due to side effects.
- TPTNS is a non-invasive procedure that can be easily self-administered at home.
- TPTNS alone has lower success rate than PTNS (48-68% Vs 60-80%). Combination of treatment can reproduce the effectiveness of PTNS while minimizing its constraints (minor bleeding, mild pain, or skin inflammation at the treatment site and its risk of infection).
- Studies have demonstrated the potential efficacy of combination of treatments, which led to the aim of this study.

# Hypothesis/Aim of the study

- Evaluation of TPTNS as 1st line (after failure of behavioural therapy) in treatment of idiopathic OAB in
- The value of adding low dose Trospium Chloride (20mg).

## Patients & Methods

#### Inclusion criteria

Adult females who were suffering from idiopathic OAB documented by cystometry.

### Exclusion criteria

- Previous medical treatment of OAB.
- UTI or BOO.
- Neurological diseases.
- Gynecological problems as genital infection, pelvic organ prolapse or genital tumors.
- Electronic implants such as heart pacemakers.
- Pregnancy.
- Seizures.

#### **Outline** of treatment

30 adult female patients presented with OAB (Failed 1st line treatment) were randomly divided into 2 groups:



- 15 Patients
- Mean age 48.73 + 16.42
- TPTNS



- 15 Patients
- Mean age 48.13 + 10.80
  TPTNS + 20 mg Trospium Chloride once daily

#### Pre-treatment & post-treatment evaluation

- 3 days voiding diary.
- OABSS Questionnaire.
- IIQ-7 Questionnaire.
- Cystometry to document detrusor overactivity.

#### Protocol

- 24 stimulation sessions (30 min. duration each). (Bipolar stimulation, Pulse Frequency 10 Hz and 250us).
- 3 sessions per week for 8 weeks.

#### Comparison between the two studied groups according to different parameters

		Group I (n=15)	Group II (n=15)	Test of sig.	P
OABSS	Pre-treatment				
	Mean ± SD.	12.67±1.95	13.0±1.31	t=0.549	0.587
	Post-treatment				
	Mean ± SD.	10.0±2.0	8.53±1.30	t=2.380	0.024
	<sup>t</sup> P <sub>1</sub>	0.001	0.001		
	Pre-treatment				
	Mean ± SD.	64.33±8.57	63.38±8.81	t=0.298	0.768
IIQ-7	Post-treatment				
	Mean ± SD.	51.86±17.26	31.99±9.26	t=3.930	0.001
	<sup>t</sup> P <sub>1</sub>	0.002	0.001		
	Pre-treatment				
	Mean ± SD.	13.13±1.64	12.87±1.85	t=0.418	0.679
Frequency	Post-treatment				
	Mean ± SD.	10.60±2.32	8.60±0.83	t=3.140	0.006
	<sup>t</sup> P1	0.003	0.001		
	Pre-treatment				
Mean	Mean ± SD.	110.40±14.92	106.15±13.12	Z=0.706	0.480
voided volume	Post-treatment				
(ml)	Mean ± SD.	138.0±37.79	178.6±25.91	Z=2.782	0.005
(1111)	<sup>Z</sup> P1	0.011	0.001		
	Pre-treatment	n=15	n=15		
Volume	Mean ± SD.	136.87±40.04	144.87±39.86	t=0.548	0.588
at 1 <sup>st</sup> sensation (ml)	Post-treatment	n=15	n=14		
	Mean ± SD.	140.47±38.11	206.07±66.37	t=3.320	0.003
	tP1	0.838	0.001		
	Pre-treatment	n=15	n=15		
Capacity (ml)	Mean ± SD.	250.13±56.24	263.40±50.45	Z =0.955	0.339
	Post-treatment	n=15	n=14*		
	Mean ± SD.	296.40±99.0	377.80±112.92	Z =2.117	0.034
	<sup>z</sup> P1	0.026	0.001		

#### Categories of OABSS before and after treatment

	Group I		Group II		
	Severe	Moderate	Severe	Moderate	
Pre-treatment	12 (80.0%)	3 (20.0%)	14 (93.3%)	1 (6.7%)	
Post-treatment	4 (26.6%)	11 (73.3%)	0 (00.0%)	15 (100%)	
MANT	0.000		0.001		

Mild= score < 5 out of 15. Moderate= score from 6 to 11. Severe= score >12.

McNp= P value for McNemar test.

#### Categories of the IIQ-7 before and after treatment in both groups

	Group I		Group II			
	Good	Moderate	Poor	Good	Moderate	Poor
Pre- treatment	0 (0%)	11 (73.3%)	4 (26.7%)	0 (0%)	11 (73.3%)	4 (26.7%)
Post- treatment	6 (40.0%)	7 (46.7%)	2 (13.3%)	14 (93.3%)	1 (6.7%)	0 (0%)
MHp	0.005			0.001		

< 50= good QoL. 50-70= Moderate QoL. > 70 = Poor QoL. MHp = p value for Marginal homogeneity test.

# Conclusions

- Multimodal treatment has significantly higher results than TPTNS alone.
- TPTNS + Low dose Trospium Chloride is safe, Non-Invasive with acceptable results to be used as a second line treatment in OAB.
- Low dose Trospium Chloride has led to improving the compliance of patients to treatment.

**Disclosure: None**